Olympus Corporation
7733.THealthcareTSEMedical Devices
Scan Results
Daily timeframeOlympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. With a market capitalization of $2.01T, it sits in mega-cap territory. It operates through two segments, Gastrointestinal Solutions and Surgical & Interventional Solutions.
Market Cap
$2.01T
Beta
0.19
P/E (TTM)
29.89
P/E (Fwd)
14.56
EPS (TTM)
$61.20
EPS (Fwd)
$125.64
ROE
8.7%
ROA
5.9%
Cash
$188.04B
Total Debt
$239.58B
Free CF
$1.49B
52W Change
-1.8%
Annual Financials
Cash vs Debt
Olympus Corporation carries $239.58B in total debt against $188.04B in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.49B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 8.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $750.12B (2022) to $997.33B (2025), reflecting a 33% increase over the period.
The relatively low beta of 0.19 suggests 7733.T is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Olympus Corporation and its sector.